SBIR/STTR Research Award
ASSAY FOR IDENTIFYING ANGIOGENIC DRUG TARGETS
Award amount
$149,974Program and phase
SBIR · Phase IAward year
2001Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PHYLONIX PHARMACEUTICALS, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION: (Applicant's Description)
Our overall aim is to use a molecular approach to isolate new genes involved
in angiogenesis. We will treat zebrafish embryos with drugs and identify genes
using subtractive library technology. Angiogenesis has been shown to be
necessary for tumor growth and inhibition of vessel formation appears to be an
excellent target for cancer therapy. The whole animal zebrafish bioassay will
streamline the drug development process for cancer and heart disease.
PROPOSED COMMERCIAL APPLICATION:
More that 20 antiangiogenic compounds are in clinical trials. Angiogenesis has been
implicated in a number of diseases including cancer, heart disease, diabetes, ulcers
and some autoimmune diseases. The market potential for screening services is
estimated to be over $100M.
Technology keywords
Not reported